Clinical Trial Consent Form Mexico (Consentimiento Informado para Estudio Clínico)

A Clinical Trial Consent Form Mexico (Formato de Consentimiento Informado para Estudio Clínico) is a written legal document through which a research participant (participante o sujeto de investigación) voluntarily acknowledges that they have been informed about the nature, objectives, risks, benefits, and alternatives of a clinical study and freely agrees to participate. In Mexico, informed consent in clinical research is governed by Articles 100 through 103 of the Ley General de Salud (LGS) and the Reglamento de la Ley General de Salud en Materia de Investigación para la Salud, which establish the mandatory conditions under which research on human subjects may be conducted. No clinical trial, experimental drug study, vaccine trial, or biomedical research involving human participants may be conducted in Mexico without a properly executed consentimiento informado that meets the requirements of Article 21 of the Reglamento.

The Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), now integrated into the Agencia Regulatoria Sanitaria (ARSAM) under the Secretaría de Salud, is the federal body responsible for authorising clinical trials of new drugs, biologics, medical devices, and vaccines in Mexico under the Ley General de Salud Article 100. COFEPRIS/ARSAM issues the Permiso de Importación Sanitaria (PIS) and the clinical trial authorisation (autorización de ensayo clínico) required before any experimental protocol may be initiated. Research institutions must also register with the Dirección General de Calidad y Educación en Salud (DGCES) of the Secretaría de Salud.

NOM-012-SSA3-2012 (Norma Oficial Mexicana) establishes the specific requirements for clinical research on human beings and is the central technical standard governing consent procedures, ethics committee oversight, and protocol management in Mexico. Under NOM-012-SSA3-2012, the consentimiento informado must be written in plain language accessible to the participant, must be reviewed and approved by the Comité de Ética en Investigación (CEI) and the Comité de Investigación of the participating institution, and must contain all information specified in the Reglamento de Investigación para la Salud Article 21.

Mexican clinical trial law distinguishes between different risk categories under Article 17 of the Reglamento de Investigación: Investigación sin riesgo (no-risk research) involving only documentary, interview, or questionnaire methods; Investigación con riesgo mínimo (minimal-risk research) including standard procedures such as blood draws and psychological testing; Investigación con riesgo mayor que el mínimo (greater than minimal risk) involving experimental interventions, new drugs, or procedures with potential for physical harm. Greater-than-minimal-risk studies require CEI approval, Comisión de Bioseguridad review where applicable, and mandatory insurance coverage (seguro de daños) for participants under Article 100 Section VI LGS.

The Ley Federal de Protección de Datos Personales en Posesión de los Particulares (LFPDPPP) and its Reglamento impose additional requirements on the handling of health data (datos sensibles) collected during clinical trials. Health data constitutes datos personales sensibles under Article 3 Section VI LFPDPPP, requiring explicit separate consent for processing and heightened security measures under the National Standards Institute guidelines issued by the Instituto Nacional de Transparencia, Acceso a la Información y Protección de Datos Personales (INAI).

México is a signatory to the Declaration of Helsinki (1964, as revised) and has adopted Good Clinical Practice (BPC — Buenas Prácticas Clínicas) standards harmonised with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline E6(R2). COFEPRIS/ARSAM requires that all sponsored clinical trials adhere to BPC standards as a condition of trial authorisation, and the consent process must comply with both Mexican law and ICH E6(R2) Section 4.8 requirements.

A Clinical Trial Consent Form Mexico is required in every situation where a research participant — whether a healthy volunteer (voluntario sano) or a patient with a medical condition — is invited to participate in a clinical study conducted in Mexico. Under Article 100 of the Ley General de Salud, the consent form is mandatory for all research involving experimental drugs, biologics, devices, new therapeutic procedures, or any intervention that subjects the participant to risk beyond ordinary clinical care.

The consentimiento informado is required when a pharmaceutical company (industria farmacéutica), contract research organisation (CRO), public hospital (hospital público del IMSS, ISSSTE, SSA, SEDENA, PEMEX), private clinic, or university medical centre initiates a Phase I, Phase II, Phase III, or Phase IV clinical trial at a COFEPRIS/ARSAM-registered site in Mexico. International sponsors conducting multi-centre trials in Mexico must ensure that the Spanish-language consent form has been approved by the local Comité de Ética en Investigación and reflects the most recent approved protocol version submitted to COFEPRIS/ARSAM.

The form is needed when a participant is a minor (menor de edad) — under 18 years — in which case the consent of the parent or legal guardian (padre, madre o tutor legal) is required in addition to the participant's assent (asentimiento) where the minor is capable of expressing a view, under Article 23 of the Reglamento de Investigación. Studies on incapacitated adults require the consent of their legal representative (representante legal) under Article 24 of the Reglamento.

A separate consent form is required when a previously enrolled participant receives a protocol amendment that introduces new risks, changes the study procedures in a material way, or affects the benefit-risk assessment — so-called re-consent (reconsentimiento). NOM-012-SSA3-2012 Section 7.1 requires that participants be informed of any new information arising during the study that may affect their willingness to continue.

The consent form is also needed when biological samples (muestras biológicas) — blood, tissue, genetic material — are collected and will be stored in a biobank (biobanco) or used for secondary research beyond the original protocol. Under the Ley General de Salud Article 103 and the Reglamento de Biobancos, additional specific consent for sample storage and future use is required separately from the general clinical trial consent. CONACYT (now CONAHCYT — Consejo Nacional de Humanidades, Ciencias y Tecnologías) guidelines apply to publicly funded research involving human biospecimens.

A valid Clinical Trial Consent Form Mexico under the Ley General de Salud Articles 100–103, NOM-012-SSA3-2012, and the Reglamento de Investigación para la Salud must include the following essential elements to satisfy COFEPRIS/ARSAM and institutional ethics committee requirements.

Study Identification: The complete name and protocol number of the clinical study, the name and address of the sponsoring entity (promotor), the principal investigator (investigador principal), the participating institution (institución participante), and the COFEPRIS/ARSAM authorisation number. Reference to the approval granted by the institutional Comité de Ética en Investigación (CEI) and Comité de Investigación must be included under NOM-012-SSA3-2012 Section 7.2.

Participant Information: Full name of the participant, date of birth, RFC or CURP (Clave Única de Registro de Población issued by the Registro Nacional de Población — RENAPO), official identity document number (INE, passport, or residence card), and the participant's declared address and contact telephone number for follow-up communications.

Study Purpose and Procedures: A clear, lay-language explanation of the purpose (objetivo) of the research, the experimental nature of the intervention, a description of all procedures to be performed — including which procedures are experimental and which are standard clinical care — and the expected duration of participation. Article 21 Section I of the Reglamento requires that the participant be informed of the study objectives before providing consent.

Risks and Benefits: A balanced description of all reasonably foreseeable risks (riesgos) and discomforts, as well as potential benefits (beneficios) to the participant or to society — and an explicit statement where the study offers no direct therapeutic benefit. Under Article 21 Section V Reglamento, the participant must be told about alternative treatments (tratamientos alternativos) available outside the study, together with their advantages and disadvantages.

Voluntary Participation and Withdrawal: An explicit statement that participation is entirely voluntary (voluntaria), that the participant may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled, and that refusal to participate will not affect their medical care at the institution. This reflects the principle of autonomía established in LGS Article 100 Section I.

Confidentiality and Data Protection: A description of how personal and health data will be processed, stored, and protected — including the legal basis under the Ley Federal de Protección de Datos Personales en Posesión de los Particulares (LFPDPPP), identification of the data controller (responsable), and the participant's rights of access, rectification, cancellation, and opposition (derechos ARCO) before the INAI. Health data constitutes datos sensibles under Article 3 LFPDPPP and requires express separate consent.

Compensation and Medical Care for Injuries: Article 100 Section VI LGS requires that the participant be informed of compensation (compensación) arrangements and of the availability of medical treatment (atención médica) in case of research-related injury. The sponsoring entity must maintain seguro de daños or equivalent indemnification coverage sufficient to compensate participants for research-related harm.

Contact Information: Names and telephone numbers of the principal investigator, the sub-investigator responsible for the site, and the CEI contact for complaints and questions — enabling the participant to ask questions, report adverse events, or file a complaint with the Comisión de Arbitraje Médico (CONAMED) at any time.

Signatures and Witnesses: The form must be signed by the participant (or legal representative) and dated, with the signature witnessed by at least one independent witness under NOM-012-SSA3-2012. The principal investigator or their designated sub-investigator must countersign. A copy of the signed form must be given to the participant; the original is retained in the Investigator Site File (Expediente del Investigador).

Forms-legal.com provides this Clinical Trial Consent Form Mexico template as a practical reference. Every consent form used in an actual clinical trial must be drafted, reviewed, and approved by qualified clinical research professionals, COFEPRIS/ARSAM-registered investigators, and the institutional Comité de Ética en Investigación — generic templates cannot substitute for protocol-specific, ethically reviewed consent documents.